MwanzoLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
$ 0.58
Kabla ya soko:(5.24%)-0.030
$ 0.55
Imefungwa: 13 Jan, 04:33:35 GMT -5 · USD · NYSEAMERICAN · Kanusho
Bei iliyotangulia
$ 0.53
Bei za siku
$ 0.51 - $ 0.58
Bei za mwaka
$ 0.48 - $ 1.61
Thamani ya kampuni katika soko
128.37M USD
Wastani wa hisa zilizouzwa
3.17M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 3.78M | 203.29% |
Matumizi ya uendeshaji wa biashara | 4.41M | 9.13% |
Mapato halisi | -3.03M | 57.33% |
Kiwango cha faida halisi | -80.29 | 85.93% |
Mapato kwa kila hisa | -0.02 | 50.37% |
EBITDA | -3.70M | 43.35% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 32.71M | -20.86% |
Jumla ya mali | 96.59M | -9.00% |
Jumla ya dhima | 31.80M | -19.48% |
Jumla ya hisa | 64.79M | — |
hisa zilizosalia | 188.84M | — |
Uwiano wa bei na thamani | 1.52 | — |
Faida inayotokana na mali | -9.63% | — |
Faida inayotokana mtaji | -13.98% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -3.03M | 57.33% |
Pesa kutokana na shughuli | -5.79M | -14.89% |
Pesa kutokana na uwekezaji | 3.89M | 83.22% |
Pesa kutokana na ufadhili | elfu -3.00 | -100.37% |
Mabadiliko halisi ya pesa taslimu | -1.86M | 23.86% |
Mtiririko huru wa pesa | -2.27M | 12.27% |
Kuhusu
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Ilianzishwa
1990
Tovuti
Wafanyakazi
72
